LONDON, United Kingdom, April 28, 2026
GSK has announced that its investigational antisense oligonucleotide therapy bepirovirsen has been accepted for priority review by the U.S. Food and Drug Administration and granted Breakthrough Therapy Designation, marking a major regulatory milestone in the fight against chronic hepatitis B (CHB). The regulatory application is supported by robust Phase III B-Well clinical trial data demonstrating statistically significant and clinically meaningful functional cure rates, positioning the therapy as a potential first-in-class innovation targeting a disease that affects more than 250 million people globally. The FDA has assigned a PDUFA target date of October 26, 2026, underscoring the urgency and importance of this therapeutic advancement in addressing a major global health burden.
Regulatory Designations Accelerate Breakthrough Innovation
The granting of Breakthrough Therapy Designation (BTD) alongside Fast Track Designation highlights the strong clinical potential of bepirovirsen to deliver substantial improvements over existing therapies for chronic hepatitis B. These regulatory pathways are designed to expedite the development and review of drugs that address serious conditions with unmet medical needs, enabling closer collaboration with the FDA and faster patient access upon approval.
Current standard treatments, including nucleos(t)ide analogues, often require lifelong therapy with limited functional cure rates of around 1%, emphasizing the urgent need for transformative therapies. Bepirovirsen’s acceptance for priority review reflects growing confidence in its ability to redefine treatment paradigms by targeting the root viral mechanisms of hepatitis B infection.
AI Integration Enhances Precision in PCI Procedures
Advertisement
Ultreon 3.0 is specifically designed to optimize percutaneous coronary intervention (PCI) procedures, which are widely used to treat blocked coronary arteries. The platform features a one-second OCT pullback technology that captures high-resolution images using infrared light, offering superior visualization compared to conventional imaging techniques while minimizing the need for contrast agents.
This is particularly beneficial for patients with kidney disease, where reduced contrast exposure is essential. The AI-powered software analyzes plaque characteristics and vessel dimensions to guide accurate stent sizing and placement, ensuring improved blood flow and better procedural outcomes. Additionally, the system provides post-procedure assessments to confirm treatment success, enhancing overall clinical confidence and consistency.
Innovative Mechanism Targets Viral RNA for Functional Cure
Bepirovirsen is a triple-action antisense oligonucleotide (ASO) designed to target and degrade hepatitis B viral RNA, including messenger RNA and pregenomic RNA, thereby inhibiting viral replication and reducing levels of hepatitis B surface antigen (HBsAg) in the bloodstream. This mechanism allows the immune system to regain control of the infection, potentially enabling a durable functional cure, defined as sustained viral suppression without ongoing treatment.
Clinical data from the global Phase III B-Well 1 and B-Well 2 trials demonstrated that patients receiving bepirovirsen in combination with standard of care achieved significantly higher functional cure rates compared to standard therapy alone, with an acceptable safety and tolerability profile. The therapy also showed enhanced efficacy in patients with lower baseline HBsAg levels, indicating its potential for targeted patient stratification and precision treatment approaches.
Transforming Chronic Hepatitis B Treatment Landscape
Chronic hepatitis B remains a leading cause of liver cirrhosis and hepatocellular carcinoma, contributing to approximately 1.1 million deaths annually worldwide. The introduction of a therapy capable of achieving functional cure represents a paradigm shift in disease management, moving beyond viral suppression toward long-term remission. From a cGxP perspective, the development of bepirovirsen reflects rigorous adherence to Good Clinical Practice (GCP), regulatory validation standards, and quality-driven drug development processes, ensuring the reliability and reproducibility of clinical outcomes.
Additionally, the therapy’s global clinical trial program, conducted across multiple countries, highlights the importance of diverse patient populations and robust data generation in modern pharmaceutical innovation. As GSK advances toward potential approval, bepirovirsen is expected to play a pivotal role in shaping the future of hepatitis B therapeutics, offering new hope for millions of patients worldwide and reinforcing the growing importance of RNA-targeted therapies in biopharma innovation.
Source: GSK press release
